Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Allison Transmission (ALSN) Tops Q2 EPS by 33c; offers guidance
• Hillman Solutions (HLMN) Reports In-Line Q2 EPS; offers guidance
• Atlas Energy Solutions Inc. (AESI) Misses Q2 EPS by 117c